In common practice, FEV1 decline [38] or exacerbation frequency [41] may influence the decision to consider initiation of the augmentation therapy in patients with severe AAT deficiency, even before all other criteria for the initiation of AAT are fulfilled [42]. The gene discussed is SERPINA1; the disease is alpha 1-antitrypsin deficiency.